25575-88-6

Usage

InChI:InChI=1/C12H16N4O4/c1-20-12(19)9(4-7-5-13-6-14-7)16-11(18)8-2-3-10(17)15-8/h5-6,8-9H,2-4H2,1H3,(H,13,14)(H,15,17)(H,16,18)/t8-,9-/m0/s1

Upstream product

• 98-79-3 L-Pyroglutamic acid 
• 1499-46-3 L-Histidine methyl ester 
• 59850-85-0 N-hydroxysuccinimide ester of pyroglutamic acid 
• 7389-87-9 L-histidine methyl ester dihydrochloride 
• 5910-47-4 L-pyroglutamic acid 2,4,5-trichlorophenyl ester 

Downstream Products

• 57818-00-5 <*>Glu-His-Pip-OMe 
• 52434-75-0 pGlu-His-Trp-Ser-Tyr 
• 142822-22-8 L-pyroglutamyl-L-histidyl-L-trypthophyl-L-seryl-L-tyrosine tert-butyl ester 
• 51871-39-7 L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosine methyl ester 
• 51952-40-0 L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycine amide hydrochloride 
• 25575-89-7 L-Pyroglutamyl-L-histidine Hydrazide 

Relevant academic research and scientific papers

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES

The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

Synthesis and biology of new thyrotropin-releasing hormone (TRH) analogues

We report synthesis and biological activities of several thyrotropin-releasing hormone (TRH) analogues in which the N-terminal pyroglutamic acid residue has been replaced with various carboxylic acids and the central histidine is modified with substituted-imidazole derivatives. Copyright

Synthesis of Gonadoliberin, a Gonadotropin Releasing Hormone

A simple laboratory synthesis of gonadoliberin was elaborated basing on classical solution methods and using minimal protection of the side-chain functions.In the final step a hexapeptide segment was condensed with the corresponding tetrapeptide and the obtained product was purified by a single step silica gel chromatography.The total efficiency of the whole synthesis was 15percent.

Polypeptide derivatives

Compounds comprising polypeptide derivatives of the formula STR1 wherein R1 is the amino acid sequence of the polypeptide minus the terminal amino acid; R is the side chain group determining the identity of the terminal amino acid; and Z is STR2 or --CH2 X wherein X is Cl, Br, or I; are provided. Precursor peptides are peptide hypothalamic releasing and inhibitory factors, opiate peptides, and fragments thereof. The derivatives act as antagonists or agonists to the precursor peptides and are particularly useful in bioassay procedures.